Articles by Bill Trombetta - Pharmaceutical Executive

ADVERTISEMENT

Articles by Bill Trombetta

Stealth Pharmas

Apr 1, 2007

Ever wonder how all those biotechs, specialty shops, and generics that make up Not Big Pharma ever manage to stay in business? Pharm Exec asked Bill Trombetta of St. Joseph's University to look at their books, analyzing their financial performance with the same metrics he uses for our annual Industry Audit. His findings may surprise you. In fact, when you check the bottom line, you just might consider changing teams.

Industry Audit

The Company of the Year: Our fifth annual report dives deep into the numbers and comes up with the industry's true top performers.
Sep 1, 2006

For the fifth year in a row, Pharm Exec invites Professor Bill Trombetta of St. Joseph's University to analyze the pharma industry's financial performance with a battery of business metrics old and new. The highlights: Two top biotechs race neck-and-neck for first place, Forest delivers another strong performance, and AstraZeneca squeezes past Johnson & Johnson and GlaxoSmithKline into the top four for the first time ever. And the winner is . . .

2005 Industry Audit

For the fourth year in a row, Pharmaceutical Executive slices and dices the numbers to learn who's really on top.
Sep 1, 2005

Not surprisingly, the biotechs hold three of the top five rankings in percent of sales invested in R&D. Even more impressive, then, are the ratios for Big Pharmas like Schering-Plough and Eli Lilly, in third and fourth place, both at a bit more than 19 percent.

Industry Audit

Running the Numbers on Pharma's Top Performers
Sep 1, 2004

In 2002, pharma had three of the top 10 profit makers: Pfizer, Merck, and Johnson & Johnson. In 2003, not a single pharma company placed in the top 10 corporate profit earners.

ADVERTISEMENT

Click here